

Additional file 8: Table S5. Association between clinicopathological factors and the presence of ctDNA in plasma.

Feature	N	ctDNA positive N (%)	p-value
Age at diagnosis, mean years (\pm SD)			0.076
	64.0 \pm 11.6	13 (86.7%)	
	42.5 \pm 6.4	2 (13.3%)	
Tumor location			0.576
Gastric	8	1 (12.5%)	
Extra-gastric	9	3 (33.3%)	
Primary tumor size, mm (\pm SD)			0.549
	98.2 \pm 50.3	13 (76.5%)	
	139 \pm 99.8	4 (23.5%)	
Mitotic count /50HPF, mm (\pm SD)			1.000
	10.7 \pm 12.5	12 (85.7%)	
	27.5 \pm 34.5	2 (14.3%)	
Tumor stage at diagnosis			0.092
Localized	8	0 (0%)	
Metastatic	10	4 (40%)	
Organs involved			0.009
1	9	1 (11%)	
2	6	2 (33.3%)	
3	2	1 (50%)	
4	1	1 (100%)	
Tumor burden, mm (\pm SD)			0.005
	101.5 \pm 70.8	14 (77.8%)	
	242.6 \pm 61.8	4 (22.2%)	
Primary mutation			1.000
KIT	14	3 (21.4%)	
PDGFRA	4	1 (25%)	
Prior lines of treatment			0.003
0	7	0 (0%)	
1	5	0 (0%)	
2	5	3 (60%)	
3	1	1 (100%)	
cfDNA ng/mL			0.271
	702.2 \pm 731.3	32 (86.5%)	
	1022.2 \pm 854.1	5 (13.5%)	

N, number; SD, standard deviation; ctDNA, circulating tumor DNA; HPF, high-power fields.